Pila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 SEK | +2.99% | +10.71% | +93.75% |
19/04 | Pila Pharma Appoints New CEO, Chief Scientific Officer | MT |
19/04 | Pila Pharma AB Announces Board and Management Appointments | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+93.75% | 70.02L | |
+40.73% | 74TCr | |
+32.83% | 60TCr | |
-6.42% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
-5.52% | 21TCr | |
+6.19% | 16TCr | |
-0.45% | 16TCr |
- Stock Market
- Equities
- PILA Stock
- News Pila Pharma AB
- Pila Pharma AB Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has Begun